Mach Ventures: Going Small in Device Investing
This article was originally published in Start Up
Executive Summary
Many investors worry that they've invested in products not companies: narrow technology plays that limit the size of the exit, or even it's likelihood of happening. But now comes a new venture fund, San Francisco-based Mach Ventures, that is betting that the real opportunity in devices comes precisely from technology plays that are, in fact, more truly products than full-fledged companies.
You may also be interested in...
Bio-Star Closes Physician-Focused Vascular Device Fund
Vascular-focused Bio-Star, which recently closed on a $26 million private equity fund, includes a distinquished roster of a dozen leading clinicians as investors.
Bio-Star Fund Taps Clinical Stars
Medical practice changes so rapidly these days that many say if device companies don't have a presence in the operating room every single day, they'll rapidly fall behind the technological curve. The same is true for VCs evaluating the market potential of new technologies, which is why many partners at successful venture firms are physicians. Now, a new VC--Bio-Star Private Equity Fund, founded and funded by practicing physicians-is going a step further.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.